Analyst Price Target is $33.60
▲ +92.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Pharvaris in the last 3 months. The average price target is $33.60, with a high forecast of $50.00 and a low forecast of $11.00. The average price target represents a 92.00% upside from the last price of $17.50.
Current Consensus is
Moderate Buy
The current consensus among 5 investment analysts is to moderate buy stock in Pharvaris. This rating has held steady since November 2023, when it changed from a Buy consensus rating.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More